Call Options

18 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$0.38 - $0.64 $11,020 - $18,560
-29,000 Reduced 29.77%
68,400 $33,000
Q1 2022

May 16, 2022

BUY
$0.55 - $0.98 $5,830 - $10,388
10,600 Added 12.21%
97,400 $65,000
Q4 2021

Feb 14, 2022

BUY
$0.9 - $1.31 $48,600 - $70,740
54,000 Added 164.63%
86,800 $86,000
Q3 2021

Nov 15, 2021

SELL
$1.21 - $1.61 $8,349 - $11,109
-6,900 Reduced 17.38%
32,800 $42,000
Q2 2021

Aug 11, 2021

BUY
$1.6 - $2.02 $27,520 - $34,744
17,200 Added 76.44%
39,700 $65,000
Q1 2021

May 17, 2021

SELL
$1.86 - $2.87 $105,276 - $162,442
-56,600 Reduced 71.55%
22,500 $45,000
Q4 2020

Feb 16, 2021

SELL
$1.65 - $2.43 $25,905 - $38,151
-15,700 Reduced 16.56%
79,100 $164,000
Q3 2020

Nov 16, 2020

SELL
$1.6 - $2.35 $122,080 - $179,305
-76,300 Reduced 44.59%
94,800 $162,000
Q2 2020

Aug 14, 2020

BUY
$1.33 - $2.76 $29,792 - $61,823
22,400 Added 15.06%
171,100 $397,000
Q1 2020

May 15, 2020

SELL
$0.97 - $2.85 $8,148 - $23,940
-8,400 Reduced 5.35%
148,700 $230,000
Q4 2019

Feb 14, 2020

BUY
$1.69 - $3.8 $234,065 - $526,300
138,500 Added 744.62%
157,100 $597,000
Q3 2019

Nov 14, 2019

SELL
$0.61 - $2.21 $25,986 - $94,146
-42,600 Reduced 69.61%
18,600 $34,000
Q1 2019

May 15, 2019

SELL
$0.51 - $0.82 $153 - $245
-300 Reduced 0.49%
61,200 $38,000
Q4 2018

Feb 14, 2019

BUY
$0.48 - $1.1 $20,208 - $46,310
42,100 Added 217.01%
61,500 $30,000
Q3 2018

Nov 14, 2018

BUY
$1.06 - $1.69 $6,466 - $10,309
6,100 Added 45.86%
19,400 $21,000
Q1 2018

May 15, 2018

SELL
$0.91 - $2.24 $22,750 - $56,000
-25,000 Reduced 65.27%
13,300 $28,000
Q4 2017

Feb 14, 2018

SELL
$0.78 - $2.1 $8,580 - $23,100
-11,000 Reduced 22.31%
38,300 $35,000
Q3 2017

Nov 14, 2017

BUY
$1.55 - $1.82 $76,415 - $89,726
49,300
49,300 $87,000

Others Institutions Holding DRRX

About DURECT CORP


  • Ticker DRRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 227,794,000
  • Market Cap $230M
  • Description
  • DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogeno...
More about DRRX
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.